The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
 
Biswajit Das
Research Funding - Illumina (Inst)
 
Amanda Peach
Research Funding - Illumina (Inst)
 
Vishnuprabha Rahul Kannan
Research Funding - Illumina (Inst); Illumina (Inst)
 
Eric Greenbank
Research Funding - Illumina (Inst); Illumina (Inst)
 
Brandie Fullmer
No Relationships to Disclose
 
Rini Pauly
Research Funding - Illumina (Inst)
 
Li Chen
Research Funding - Illumina (Inst)
Expert Testimony - Illumina (Inst)
 
Ting-Chia Chang
Research Funding - Illumina (Inst)
 
Jennifer LoCoco
Employment - Illumina
Stock and Other Ownership Interests - Illumina; InhibRx; Roche
Patents, Royalties, Other Intellectual Property - Patent application pending through work performed in my role at Illumina, Inc (Inst)
 
Yuri Kotliarov
No Relationships to Disclose
 
Keith Flaherty
Leadership - Clovis Oncology; Khora Therapeutics; Kinnate Biopharma; Scorpion Therapeutics; Strata Oncology
Stock and Other Ownership Interests - Alterome Therapeutics; ALX Oncology; Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; Flinr Therapeutics; FOGPharma; IntrECate; Kinnate Biopharma; Loxo; Monopteros Therapeutics; Nextech Invest; Oncoceutics; PIC Therapeutics; PreDICTA; Scorpion Therapeutics; Soley Therapeutics; Strata Oncology; Transcode Therapeutics; Tvardi Therapeutics; Vibliome Therapeutics; X4 Pharma; xCures
Consulting or Advisory Role - Debiopharm Group; Immagene; Karkinos Healthcare; Lilly; Novartis; OmRx Oncology; Oncoceutics; Quanta Therapeutics; Takeda; Tvardi Therapeutics
 
Stanley Hamilton
Research Funding - CytoImmune Therapeutics (Inst); Intima (Inst); Iovance Biotherapeutics (Inst); Minerva Biotechnologies (Inst)
 
Lyndsay Harris
No Relationships to Disclose
 
Alice Chen
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst)
 
Traci Pawlowski
Employment - Illumina
Stock and Other Ownership Interests - BMY; Illumina; Novo Nordisk
 
Lisa McShane
No Relationships to Disclose
 
Peter O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
 
James Doroshow
No Relationships to Disclose
 
Chris Karlovich
Research Funding - Illumina (Inst)
(OPTIONAL) Uncompensated Relationships - Illumina